Publications by authors named "N İnanc"
CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in patients with AS undergoing first-line (1st-line) and later (≥2nd-line) treatment in clinical practice.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the north-south gradient hypothesis, suggesting that individuals with rheumatoid arthritis (RA) in southern regions (like Turkey) tend to have a younger age of onset and milder disease than those in northern regions (like Denmark).
- In a comparison of 223 treatment-naïve RA patients from Denmark and Turkey, it was found that Danish patients had a later onset age (60 years) and more severe joint symptoms compared to Turkish patients (51 years).
- The findings support the hypothesis and reveal that Danish patients have more genetic risk factors for RA, prompting the need for future research into the genetic and environmental influences on these regional differences.
Article Synopsis
- * It included 116 patients with pSS, assessing salivary flow rates, eye dryness, and psychological health using various patient-reported outcome measures like the Brief Resilience Scale (BRS) and the Hospital Anxiety and Depression Scale (HADS).
- * Findings indicated lower resilience scores in patients experiencing recurrent parotitis, and those with both dry mouth and dry eyes, suggesting these factors, along with anxiety and depression, may negatively influence psychological resilience in pSS patients.
Objective: The pathogenesis of periodontal diseases is partially driven by oxidative stress. However, studies on the relationship between periodontitis and the inflammatory load of diet are still insufficient. Therefore, this study aimed to examine the relationship between the diet's inflammatory load and periodontitis and clinical attachment loss (CAL).
View Article and Find Full Text PDFObjectives: This study aims to investigate the effect of age on disease activity and biological treatment in patients with ankylosing spondylitis (AS).
Patients And Methods: A total of 811 AS patients registered in the TURKBIO registry database between 2011 and 2019 were categorized according to their age at the time of entry into the registry and assigned to one of two groups: young patients, defined as <60 years of age (n=610), and those aged ≥60 years (n=201) were recorded as elderly patients. Demographic, clinical, and laboratory characteristics, along with disease activity markers and other follow-up parameters, as well as current and prior treatments, were electronically recorded during each visit using open-source software.